<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477242</url>
  </required_header>
  <id_info>
    <org_study_id>H-1105-114-364</org_study_id>
    <nct_id>NCT01477242</nct_id>
  </id_info>
  <brief_title>The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department</brief_title>
  <official_title>The Effect of Oral Ondansetron During Intramuscular Ketamine Use in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the anti-emetic effect of oral ondansetron. For this
      evaluation, the investigators will perform a multi-center, double-blind, placebo-controled,
      randomized study. The investigators assumption is that oral ondansetron prior to
      intramuscular ketamine will reduce the occurrence of ketamine-induced vomiting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods

        -  a multi-center, double-blind, placebo-controled, randomized study ( 4 tertiary hospital
           ED)

        -  survey for the occurrence of vomiting at ED and after discharge

      Primary outcome

        -  the number of vomiting at ED and at home

      Secondary outcome

        -  parent's satisfaction and ED length of stay
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vomiting at ED stay and 12 hours after discharge</measure>
    <time_frame>the participants will be followed for the duration of ED stay (upto 24hr) and 12hours after discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>parent's satisfaction</measure>
    <time_frame>satisfaction will be surveyed within 48hours after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of emergency department stay</measure>
    <time_frame>length of stay will be calculated upto 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Sedation and Analgesia</condition>
  <condition>Side Effect of Drug</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron use group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>2mg (5mL) in &lt; 15 kg and 4mg (10mL) in 15kg to 30kg</description>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Zofran zydis</other_name>
    <other_name>vomiset</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children under 18 years of age

          -  children who are planned to admit ketamine intramuscular injection

          -  children with ASA classification class I or II

        Exclusion Criteria:

          -  don't want to enroll to study

          -  children with condition of contraindication of ketamine (IICP, IIOP, psychosis, brain
             tumor, thyroid disease, porphyria)

          -  children with condition of contraindication of ondansetron (hypersensitivity to 5-HT3
             antagonist, Long QT syndrome, severe liver failure, obstructive ileus)

          -  children under 3 months of age

          -  children whose weight are over 30 kg

          -  children managed by other drug with ketamine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Do Kyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Do Kyun Kim, M.D.</last_name>
    <phone>82-2-2072-0238</phone>
    <email>birdbeak@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do Kyun Kim, M.D.</last_name>
      <phone>82-2-2072-0238</phone>
    </contact>
    <investigator>
      <last_name>Do Kyun Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jae Yun Jung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Do Kyun Kim</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <keyword>vomiting</keyword>
  <keyword>anti-emetics</keyword>
  <keyword>ketamine</keyword>
  <keyword>sedation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

